NCT00080353View on ClinicalTrials.gov

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2008

Conditions
Melanoma
Interventions
DRUG

IL-2

DRUG

gp100:209-217

DRUG

OKT3

DRUG

rF-go 100P209

DRUG

Montanide ISA 51

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00080353 - Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma | Biotech Hunter | Biotech Hunter